Loading
A phase 2 trial of Catumaxomab in Ovarian cancer, run by Neovii Biotech, completed.
Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer is a phase 2 interventional study registered as NCT00563836 by Neovii Biotech, with 41 participants recorded, started 2007-11 and reaching its primary completion in 2008-09. Interventions recorded: Catumaxomab. Conditions recorded: Ovarian Cancer, Epithelial Ovarian Cancer.
Linked to the drug Catumaxomab because the registry names it among its interventions and Ovarian cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Neovii, Catumaxomab, Ovarian cancer and the tag pipeline.
Shares Catumaxomab, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/